發(fā)布時(shí)間：2018-05-24 00:47

  本文選題：罕用藥 + 研發(fā)激勵(lì)��； 參考：《中國(guó)藥房》2017年16期

【摘要】：目的:為構(gòu)建和完善我國(guó)的罕用藥研發(fā)激勵(lì)政策提供參考和建議。方法:從罕用藥的立法沿革、研發(fā)罕用藥的激勵(lì)措施與效果方面對(duì)美國(guó)和歐盟的罕用藥研發(fā)激勵(lì)政策進(jìn)行對(duì)比,并為我國(guó)完善相關(guān)政策提供建議。結(jié)果與結(jié)論:美國(guó)與歐盟的罕用藥激勵(lì)政策分別始于1983年美國(guó)《罕用藥法案》與1999年歐盟《罕用藥管理規(guī)范》,之后通過(guò)不斷完善,形成了較為完備的體系。美國(guó)與歐盟在罕用藥的認(rèn)定標(biāo)準(zhǔn)、認(rèn)定程序、具體激勵(lì)措施(研發(fā)資助、稅收減免、費(fèi)用減免、微型與中小企業(yè)額外激勵(lì)、市場(chǎng)獨(dú)占、特殊審批程序)等方面有所差異,如在費(fèi)用減免方面,美國(guó)對(duì)處方申請(qǐng)費(fèi)用、生產(chǎn)費(fèi)用和藥物確認(rèn)費(fèi)用進(jìn)行減免,而歐盟對(duì)協(xié)議幫助費(fèi)用、初始和后續(xù)要求費(fèi)用,審批前的檢查費(fèi)用和首次上市申請(qǐng)費(fèi)用依類(lèi)型按一定比例進(jìn)行減免。罕用藥激勵(lì)政策推行后,其資格認(rèn)定數(shù)量及上市數(shù)量大幅增加、微型與中小型企業(yè)成為罕用藥研發(fā)的生力軍、研發(fā)投資涵蓋各類(lèi)疾病治療領(lǐng)域、罕用藥研發(fā)成為藥物創(chuàng)新和生物技術(shù)發(fā)展的主要方向。我國(guó)應(yīng)該盡快確定罕用藥研發(fā)激勵(lì)的相關(guān)立法、設(shè)立罕用藥的資格認(rèn)定、從多方面入手完善罕用藥研發(fā)激勵(lì)具體措施,同時(shí)加強(qiáng)與其他國(guó)家在罕用藥資格認(rèn)定和研發(fā)激勵(lì)方面的合作。
[Abstract]:Objective: to provide references and suggestions for the construction and improvement of the incentive policy for the research and development of rare drugs in China. Methods: from the legislative evolution of rare drugs, the incentive measures and effects of the research and development of rare drugs, the incentive policies of the United States and the European Union were compared, and suggestions were provided for the improvement of the relevant policies in China. Results & conclusion: the incentive policies of the United States and the European Union began in 1983 and 1999 respectively, and formed a relatively complete system through continuous improvement. There are differences between the United States and the European Union in terms of the standards, procedures, specific incentives (R & D aid, tax credit, fee relief, additional incentives for micro and small enterprises, market monopoly, special approval procedures, etc.) for rare drugs. For example, in the case of fee reduction, the United States waives prescription application fees, production costs and drug recognition fees, while the European Union pays for agreement assistance costs, initial and follow-up requirements, The examination fee and the initial listing application fee shall be reduced by certain proportion according to the type. After the implementation of the incentive policy on rare drugs, the number of qualifications and the number of listed ones have increased substantially. Micro, small and medium-sized enterprises have become the new force in the research and development of rare drugs, and the investment in R & D covers all kinds of disease treatment fields. Research and development of rare drug use has become the main direction of drug innovation and biotechnology development. As soon as possible, our country should determine the relevant legislation on the incentive for the research and development of rare drugs, establish the qualifications for the research and development of the rare drugs, and improve the specific measures for encouraging the research and development of the rare drugs from many aspects. At the same time, strengthen the cooperation with other countries on qualification recognition and R & D incentives.
【作者單位】： 沈陽(yáng)藥科大學(xué)工商管理學(xué)院;
【基金】：國(guó)家社會(huì)科學(xué)基金項(xiàng)目(No.13CFX086) 遼寧省教育廳科學(xué)研究一般項(xiàng)目(No.W2014119) 沈陽(yáng)藥科大學(xué)中青年教師事業(yè)發(fā)展支持計(jì)劃
【分類(lèi)號(hào)】：R95

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陶勇,邵元福,張純,郭澄,雷嵐;日本的罕用藥管理制度[J];中國(guó)藥學(xué)雜志;2002年06期

2 趙曉春,徐飛,王勇;我國(guó)建立罕用藥管理制度的策略思考[J];醫(yī)學(xué)與哲學(xué);2003年07期

3 李偉;;各國(guó)罕用藥管理制度比較研究[J];上海食品藥品監(jiān)管情報(bào)研究;2008年02期

4 曾智;楊?lèi)?令狐昌黎;湯涵;;擬建我國(guó)罕用藥政策制度的探討與建議[J];中國(guó)藥房;2009年10期

5 袁芳;沈舜義;;罕用藥新品種開(kāi)發(fā)及臨床評(píng)價(jià)[J];世界臨床藥物;2011年05期

6 丁錦希;季娜;;中美罕用藥特殊注冊(cè)審評(píng)制度的比較研究[J];中國(guó)醫(yī)藥工業(yè)雜志;2011年11期

7 林禹鴻;吳曉明;;臺(tái)灣罕用藥法律制度給我們的啟示[J];法治研究;2012年06期

8 林禹鴻;吳曉明;;歐盟罕用藥管理的成就與經(jīng)驗(yàn)及其對(duì)中國(guó)的啟示[J];中國(guó)現(xiàn)代應(yīng)用藥學(xué);2012年12期

9 田圓圓;;美國(guó)罕用藥風(fēng)險(xiǎn)管理措施簡(jiǎn)介與分析以及對(duì)我國(guó)的啟示[J];中國(guó)執(zhí)業(yè)藥師;2013年01期

10 張楠;沈愛(ài)玲;;我國(guó)罕用藥有關(guān)激勵(lì)政策法規(guī)現(xiàn)狀及進(jìn)展[J];中國(guó)醫(yī)院藥學(xué)雜志;2013年01期

相關(guān)會(huì)議論文 前3條

1 楊莉;陳玉文;黃哲;孟令全;連桂玉;;罕用藥獨(dú)占制度研究[A];2009年中國(guó)藥學(xué)會(huì)藥事管理專(zhuān)業(yè)委員會(huì)年會(huì)暨“國(guó)家藥物政策與《藥品管理法》修訂研究”論壇論文文集[C];2009年

2 王英曉;許q，

本文編號(hào)：1927041